Please login to the form below

Not currently logged in
Email:
Password:

OPEN Health acquires Lane Earl Cox

Recently launched healthcare communications firm OPEN Health has bought Lane Earl Cox, which will be rebranded as OPEN LEC

Healthcare advertising agency Lane Earl Cox (LEC) has been acquired by communications company OPEN Health, which was launched in January 2011.

Lane Earl Cox (LEC) will be rebranded as OPEN LEC. Matthew Baker, formerly deputy managing director of LEC, becomes MD of OPEN LEC, as well as taking a partnership in OPEN Health.

This sees him re-united with former Huntsworth Health colleagues David Rowley, Sandy Royden and Marcus Perry. Mike Lane and David Earl, founder members of LEC, will become consultants to the business.

David Rowley, partner of OPEN Health, said: "This is an exciting opportunity. LEC are a well known and respected agency and together we form a team with amazing expertise and experience ready to face the challenges of healthcare communications today and tomorrow."

OPEN Health has also appointed Margot Rozga as associate partner. Rozga's primary responsibility will be to build the medical communications business with Sandy Royden.

LEC was established in 1993 and has worked on brands including Lipitor, Losec, Vioxx, Aricept, Symbicort, Atripla and Prozac.

7th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...